Pfizer Ends Premarin Sales in Canada

The drugmaker will stop supplying its hormone therapy vaginal cream in Canada after a shortage that began in June.

Updated on Nov. 12, 2026 in Women’s Health

Photograph of a half-empty steel storage shelf holding unlabeled amber glass vials and plain white cartons in a cool, clinical pharmaceutical storage room.
Pfizer Canada will stop supplying its Premarin vaginal cream after a shortage that began in June, citing an internal review and no new safety concerns. AI Illustration. Upload story photo >

Live Poll

Do you think drug companies can be trusted to keep essential medications stocked in Canada?

Pfizer Canada confirmed that no further batches of Premarin vaginal cream will be supplied, following a shortage in Canada that has persisted since June. The decision was not related to any new safety, efficacy or quality concerns, according to the company's internal review.

Why it matters

Premarin is a hormone replacement therapy used by women, and the discontinuation removes one option from the Canadian market at a time when supply of other estradiol products is also constrained. Health Canada has reported intermittent shortages of certain estradiol transdermal patches expected to continue until early 2027.

Premarin is sold in Canada as a vaginal cream and in three oral tablet strengths, and existing tablet inventories in the 0.3 mg, 0.625 mg and 1.25 mg strengths are expected to last until about mid-2027. The source does not say whether tablet supply will continue beyond that point.

The players

Pfizer

Pfizer is a major American pharmaceutical company that manufactures Premarin, a long-established hormone replacement therapy.

Health Canada

Health Canada is the federal department responsible for regulating health products and drugs in Canada, including monitoring product shortages.

The details

Pfizer Canada confirmed to Reuters that no further batches of Premarin vaginal cream will be supplied after the product has been in shortage since June. The company said the decision applies only to Canada, does not affect Premarin Intravenous, and follows an internal review, while Pfizer suspended sales of the vaginal cream in India in July.

Timeline

  1. June 2026: Premarin vaginal cream shortage in Canada began.

  2. July 2026: Pfizer suspended Premarin vaginal cream sales in India.

  3. November 2026: Health Canada reported shortages of certain estradiol patches made by Bayer and Sandoz.

  4. Mid-2027: Existing Premarin tablet inventories are expected to last until about this point.

Health Landscape

The discontinuation comes after the FDA removed long-standing safety warnings on hormone therapy in November 2025, a shift that broadened how these drugs are prescribed. Supply constraints in Canada now run against that backdrop, with Premarin shortages and estradiol patch shortages affecting access to menopausal hormone therapy.

Canadians currently using Premarin vaginal cream will need to discuss alternatives with their prescriber as supply ends. Existing Premarin tablet inventories are expected to last until about mid-2027, so patients on tablets have a longer window to plan.

The takeaway

Patients relying on Premarin should speak with a healthcare provider now about switching options before supply runs out. Checking current inventory with a pharmacy can help avoid gaps in treatment.

Further reading

Explore more coverage of Women’s Health for context on hormone therapy and menopause care in Canada.

Live Poll

Do you think drug companies can be trusted to keep essential medications stocked in Canada?